InnFocus MicroShunt

Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Managing glaucoma with surgical procedures (plural)The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
Aqueous drainage tube provides trabeculectomy-like efficacyIn a study including 23 eyes with a transscleral micro-lumen aqueous drainage tube after failing maximum tolerated medication, reductions in the mean IOP were observed as well as in the mean number of medications per day.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
Device makers swing for fence with new technologiesDevice manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.
Minimally invasive glaucoma procedure replicates trabeculectomy efficacy with superior safety profileTwenty-two of 23 eyes with a trans-scleral micro-lumen aqueous drainage tube implanted after failing maximum tolerated medication were evaluable at 3 years.
New glaucoma devices bring new dimension of treatment
Novel microshunt providing dramatic and stable IOP controlAn investigational glaucoma device that shunts aqueous from the anterior chamber to a sub-conjunctival/sub-Tenon’s pouch is being evaluated in a prospective study of 35 eyes operated on at two centers.